1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases.

Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A

Lancet (London, England)1 Apr 1977Cited by 372 (Europe PMC)

PMID67283DOI10.1016/s0140-6736(77)91197-7PepBankPUB-00067283

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanCase report or seriesEfficacy outcome
After D.D.A.V.P., dental extraction and major surgery succeeded in six patients with mild haemophilia and two with von Willebrand's disease.
In plain wordsAfter D.D.A.V.P., dental extraction and major surgery succeeded in six patients with mild haemophilia and two with von Willebrand's disease.
Peptide
Desmopressin
Outcome
Not applicableSuccessful dental extraction and major surgery
Study
n = 8
Outcome group
Bleeding and clotting · Whole body
Studied dose
Dose not stated · infusionAs given in this study (human).
Measurements
Successful surgery
6 patients
mild haemophilia
Successful surgery
2 patients
von Willebrand's disease
Source sentences
Summary
VII C.A. levels up to 100% of average normal were achieved and dental extraction and major surgery (such as cholecystectomy, thoracotomy, and two tonsillectomies) were carried out successfullly in six patients with mild haemophilis and in two with vWd.
2 context sentences(design, population, supporting numbers)
Summary · context
A higher D.D.A.V.P. dosage (0.4-0.5 microng/kg) in patients with higherstarting VII C.A. (9% or more) was followed by a more marked response (four to six fold).
Summary · context
The possibility was therefore evaluated that such an autologous factor-VII response might be haemostatically effective, allowing patients to undergo surgery without plasma concentrates.
Report a problemFND-0006728306
02HumanCase report or seriesActivity measurement
In patients with moderate or mild haemophilia, D.D.A.V.P. was followed by a two to three fold rise in factor-VIII coagulant activity.
In plain wordsIn patients with moderate or mild haemophilia, factor-VIII clotting activity rose two to three fold after D.D.A.V.P. compared with before administration.
Peptide
Desmopressin
Outcome
IncreaseFactor-VIII coagulant activity at lower dose
Study
n = 4
Comparator
Before administration
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 microng/kg before dental surgery and repeated in the early postoperative period · infusionAs given in this study (human).
Measurements
Factor-VIII activity increase
2 to 3 fold
0.3 microng/kg
Source sentences
Summary
0.3 microng/kg of D.D.A.V.P. given before dental surgery and repeated in the early postoperative period was followed by a two to three fold rise in factor-VIII coagulant activity (VII C.A.) in four patients with moderate and mild haemophilia.
1 context sentence(design, population, supporting numbers)
Summary · context
The possibility was therefore evaluated that such an autologous factor-VII response might be haemostatically effective, allowing patients to undergo surgery without plasma concentrates.
Report a problemFND-0006728301
03HumanCase report or seriesEfficacy outcome
After D.D.A.V.P., two haemophilia patients had no abnormal bleeding after dental extraction.
In plain wordsAfter D.D.A.V.P., two haemophilia patients had no abnormal bleeding after dental extraction.
Peptide
Desmopressin
Outcome
Not applicableNo abnormal bleeding after dental extraction
Study
n = 4
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 microng/kg before dental surgery and repeated in the early postoperative period · infusionAs given in this study (human).
Measurements
No abnormal bleeding
2 patients
dental extraction
Source sentences
Summary
In two, there was no abnormal bleeding after dental extraction,
2 context sentences(design, population, supporting numbers)
Summary · context
0.3 microng/kg of D.D.A.V.P. given before dental surgery and repeated in the early postoperative period was followed by a two to three fold rise in factor-VIII coagulant activity (VII C.A.) in four patients with moderate and mild haemophilia.
Summary · context
The possibility was therefore evaluated that such an autologous factor-VII response might be haemostatically effective, allowing patients to undergo surgery without plasma concentrates.
Report a problemFND-0006728302
04HumanCase report or seriesEfficacy outcome
After D.D.A.V.P., two haemophilia patients required plasma concentrates to control socket oozing after dental extraction.
In plain wordsAfter D.D.A.V.P., two haemophilia patients needed plasma concentrates to control bleeding from tooth sockets.
Peptide
Desmopressin
Outcome
Not applicablePlasma concentrates needed for socket oozing
Study
n = 4
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 microng/kg before dental surgery and repeated in the early postoperative period · infusionAs given in this study (human).
Measurements
Required plasma concentrates
2 patients
socket oozing
Source sentences
Summary
In two, there was no abnormal bleeding after dental extraction, whereas plasma concentrates were necessary to control oozing from the sockets in the remaining two patients.
2 context sentences(design, population, supporting numbers)
Summary · context
0.3 microng/kg of D.D.A.V.P. given before dental surgery and repeated in the early postoperative period was followed by a two to three fold rise in factor-VIII coagulant activity (VII C.A.) in four patients with moderate and mild haemophilia.
Summary · context
The possibility was therefore evaluated that such an autologous factor-VII response might be haemostatically effective, allowing patients to undergo surgery without plasma concentrates.
Report a problemFND-0006728303
05HumanCase report or seriesActivity measurement
In patients with starting VII C.A. of at least 9%, higher-dose D.D.A.V.P. was followed by a four to six fold response.
In plain wordsIn patients with higher starting clotting activity, factor-VIII activity rose four to six fold after higher-dose D.D.A.V.P. compared with before administration.
Peptide
Desmopressin
Outcome
IncreaseFactor-VIII coagulant response at higher dose
Study
n: not reported in source
Comparator
Before administration
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.4-0.5 microng/kg · infusionAs given in this study (human).
Measurements
Response
4 to 6 fold
higher-dose D.D.A.V.P.
Source sentences
Summary
A higher D.D.A.V.P. dosage (0.4-0.5 microng/kg) in patients with higherstarting VII C.A. (9% or more) was followed by a more marked response (four to six fold).
1 context sentence(design, population, supporting numbers)
Summary · context
The possibility was therefore evaluated that such an autologous factor-VII response might be haemostatically effective, allowing patients to undergo surgery without plasma concentrates.
Report a problemFND-0006728304
06HumanCase report or seriesActivity measurement
In patients with haemophilia or von Willebrand's disease, D.D.A.V.P. was followed by VII C.A. levels up to 100% of average normal.
In plain wordsIn patients with haemophilia or von Willebrand's disease, clotting activity reached up to 100% of average normal after D.D.A.V.P.
Peptide
Desmopressin
Outcome
Not applicableAchieved factor-VIII coagulant activity
Study
n: not reported in source
Outcome group
Bleeding and clotting · Whole body
Studied dose
Dose not stated · infusionAs given in this study (human).
Measurements
VII C.A.
≤ 100 % of average normal
maximum achieved level
Source sentences
Summary
VII C.A. levels up to 100% of average normal were achieved and dental extraction and major surgery (such as cholecystectomy, thoracotomy, and two tonsillectomies) were carried out successfullly in six patients with mild haemophilis and in two with vWd.
2 context sentences(design, population, supporting numbers)
Summary · context
A higher D.D.A.V.P. dosage (0.4-0.5 microng/kg) in patients with higherstarting VII C.A. (9% or more) was followed by a more marked response (four to six fold).
Summary · context
The possibility was therefore evaluated that such an autologous factor-VII response might be haemostatically effective, allowing patients to undergo surgery without plasma concentrates.
Report a problemFND-0006728305
07HumanCase report or seriesActivity measurement
In patients treated with D.D.A.V.P., induced autologous VII C.A. had a mean half-life of 9.4 h, ranging from 7.5 to 11.6.
In plain wordsIn patients treated with D.D.A.V.P., the induced clotting activity had a mean half-life of 9.4 hours.
Peptide
Desmopressin
Outcome
Not applicableAutologous VII C.A. half-life
Study
n: not reported in source
Outcome group
Bleeding and clotting · Whole body
Studied dose
Dose not stated · infusionAs given in this study (human).
Measurements
Mean half-life
9.4 h
autologous VII C.A.
Half-life range
7.5 to 11.6 h
autologous VII C.A.
Source sentences
Summary
The mean half-life of autologous VII C.A. was 9.4 h (range 7.5-11.6).
2 context sentences(design, population, supporting numbers)
Summary · context
0.3 microng/kg of D.D.A.V.P. given before dental surgery and repeated in the early postoperative period was followed by a two to three fold rise in factor-VIII coagulant activity (VII C.A.) in four patients with moderate and mild haemophilia.
Summary · context
The possibility was therefore evaluated that such an autologous factor-VII response might be haemostatically effective, allowing patients to undergo surgery without plasma concentrates.
Report a problemFND-0006728307
08HumanCase report or seriesSafety outcome
In patients treated with D.D.A.V.P., plasma osmolality showed no consistent variation after drug administration.
In plain wordsIn patients treated with D.D.A.V.P., blood osmolality showed no consistent change compared with before drug administration.
Peptide
Desmopressin
Outcome
Direction not reportedPlasma osmolality
Study
n: not reported in source
Comparator
Before drug administration
Outcome group
Fluid And Electrolyte Balance · Whole body
Studied dose
Dose not stated · infusionAs given in this study (human).
Source sentences
Summary
Plasma and urine osmolality showed no consistent variation after drug administration.
2 context sentences(design, population, supporting numbers)
Summary · context
1-Deamino-8-d-arginine vasopressin (D.D.A.V.P.) infusion causes a marked increase in factor-VIII (antihaemophilic-factor)-related properties in patients with moderate and mild haemophilia and von Willebrand's disease (vWd).
Summary · context
The possibility was therefore evaluated that such an autologous factor-VII response might be haemostatically effective, allowing patients to undergo surgery without plasma concentrates.
Report a problemFND-0006728308
09HumanCase report or seriesSafety outcome
In patients treated with D.D.A.V.P., urine osmolality showed no consistent variation after drug administration.
In plain wordsIn patients treated with D.D.A.V.P., urine osmolality showed no consistent change compared with before drug administration.
Peptide
Desmopressin
Outcome
Direction not reportedUrine osmolality
Study
n: not reported in source
Comparator
Before drug administration
Outcome group
Fluid And Electrolyte Balance · Whole body
Studied dose
Dose not stated · infusionAs given in this study (human).
Source sentences
Summary
Plasma and urine osmolality showed no consistent variation after drug administration.
2 context sentences(design, population, supporting numbers)
Summary · context
1-Deamino-8-d-arginine vasopressin (D.D.A.V.P.) infusion causes a marked increase in factor-VIII (antihaemophilic-factor)-related properties in patients with moderate and mild haemophilia and von Willebrand's disease (vWd).
Summary · context
The possibility was therefore evaluated that such an autologous factor-VII response might be haemostatically effective, allowing patients to undergo surgery without plasma concentrates.
Report a problemFND-0006728309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT00816127

Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction

Icahn School of Medicine at Mount Sinain = 36Oct 2003 to May 2007

Liver Cirrhosis · Coagulopathy

Trial page ClinicalTrials.govUpdated 1 Jan 2009

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.